Adaptimmune Therapeutics PLC — Director's Dealing 2022

May 24, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2022-05-20

Reporting Person: Wood Gavin (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-20	Ordinary Shares with a nominal value of GBP0.001 per share	P	39000	$0.2904	Acquired	96000	Direct

Footnotes

F1: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by Gavin Wood. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc.

F2: The 39,000 ordinary shares reported in Column 4 are represented by 6,500 ADSs.

F3: The price reported in Column 4 of $0.2904 per ordinary share is derived from the purchase price paid on May 20, 2022 of $1.7423 per ADS divided by six.

F4: The 96,000 ordinary shares reported in Column 5 include 57,000 ordinary shares represented by 9,500 ADSs owned by Mr. Wood prior to the purchase reported in Column 4. These shares are held in the form of ADSs by Mr. Wood.